Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
1,863
Views
0
CrossRef citations to date
0
Altmetric
Articles

Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen

Binbin Laia Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, People’s Republic of ChinaView further author information
,
Qitian Mub Laboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, People’s Republic of ChinaView further author information
,
YanLi Zhanga Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, People’s Republic of ChinaView further author information
,
Ying Chenb Laboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, People’s Republic of ChinaView further author information
,
Xiao Yana Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, People’s Republic of ChinaView further author information
&
Guifang Ouyanga Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 751-757 | Published online: 23 Sep 2021

References

  • Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018;59:274–287.
  • Koenig KL, Sahasrabudhe KD, Sigmund AM, et al. AML with myelodysplasia-related changes: development. Challenges, and Treatment Advances. Genes (Basel). 2020;11:845.
  • Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:721–749.
  • Contieri B, Duarte BKL, Lazarini M. Updates on DNA methylation modifiers in acute myeloid leukemia. Ann Hematol. 2020;99:693–701.
  • Wei G, Ni W, Chiao JW, et al. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011;4:46.
  • Liu J, Jia JS, Gong LZ, et al. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC]. Zhonghua Xue Ye Xue Za Zhi. 2018;39:734–738.
  • Pepe S, Scalzulli E, Colafigli G, et al. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. Ann Hematol. 2020;99:2405–2416.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649.
  • Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28:556–561.
  • Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670–2677.
  • Zhang JL, Cao YP, Li JG. [Efficacy and safety of decitabine combined with CAG (cytarabine, aclarubicin, G-CSF) for patients with intermediate or high risk myelodysplastic syndrome and acute myeloid leukemia: a meta-analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019;27:494–503.
  • Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6:6448–6458.
  • Bocchia M, Candoni A, Borlenghi E, et al. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. Hematol Oncol. 2019;37:447–455.
  • Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma. 2014;55:1533–1537.
  • van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol. 2011;155:599–606.
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–2221.
  • Qin W, Chao HY, Cai XH, et al. [Coexisting mutations in NPM1-mutated elderly adults with acute myeloid leukemia]. Zhonghua Yi Xue Za Zhi. 2019;99:3152–3157.
  • Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232–1240.
  • Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–2036.
  • Becker H, Pfeifer D, Ihorst G, et al. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. Ann Hematol. 2020;99:1551–1560.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.